Jefferies Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,630
Closed -$1.79M – 1643
2026
Q2
$1.79M Buy
10,630
+7,584
+249% +$1.13M 0.01% 729
2026
Q1
$401K Sell
3,046
-42,930
-93% -$5.7M ﹤0.01% 1299
2025
Q4
$6.52M Buy
+45,976
New +$6.66M 0.03% 431
2025
Q2
– Sell
-4,500
Closed -$498K – 1650
2025
Q1
$498K Buy
+4,500
New +$570K ﹤0.01% 1046
2024
Q4
– Sell
-4,390
Closed -$506K – 1743
2024
Q3
$506K Sell
4,390
-390
-8% -$53.5K ﹤0.01% 975
2024
Q2
$658K Sell
4,780
-1,155
-19% -$158K 0.01% 878
2024
Q1
$819K Sell
5,935
-691
-10% -$94.4K 0.01% 894
2023
Q4
$873K Buy
+6,626
New +$763K 0.01% 1011
2023
Q1
– Sell
-14,511
Closed -$1.73M – 1865
2022
Q4
$1.73M Buy
+14,511
New +$1.7M 0.01% 704

Other funds holding NBIX

Jefferies Financial Group's NBIX Position: Q3 2026 in Review

Jefferies Financial Group sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 10,630 shares — an estimated $1.79M sold.

Jefferies Financial Group first reported a position in NBIX in Q4 2022 and held it in 9 quarters. The position peaked at $6.52M in Q4 2025. 770 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Jefferies Financial Group reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 10,630 Neurocrine Biosciences shares in Q3 2026, an estimated $1.79M.
  • Jefferies Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 9 quarters.
  • Jefferies Financial Group's Neurocrine Biosciences position peaked at $6.52M in Q4 2025.
  • 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.